Research programme: eye disorder gene therapies - Ophthotech Corporation

Drug Profile

Research programme: eye disorder gene therapies - Ophthotech Corporation

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OphthoTech Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Eye-Disorders

Highest Development Phases

  • Research Eye-Disorders

Most Recent Events

  • 07 Jun 2018 University of Florida Research Foundation and the University of Pennsylvania enter into a licensing agreement with Ophthotech for the deveopment ofadeno-associated virus (AAV) gene therapy product
  • 07 Jun 2018 Ophthotech Corporation plans a phase I/II trial for Retinitis pigmentosa
  • 07 Jun 2018 Ophthotech Corporation plans IND-enabling studies for Retinitis pigmentosa in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top